<div class="tables frame-topbot rowsep-0 colsep-0" id="tbl2">
<div class="captions"><span id="cecap60"><p id="spara110"><span class="label">Table 2</span>. Adverse events</p></span></div>
<div class="groups"><table>
<thead><tr class="valign-top rowsep-1">
<th scope="col"></th>
<th scope="col"></th>
<th scope="col" class="align-left"><strong>Dulaglutide 1·5 mg (n=192)</strong></th>
<th scope="col" class="align-left"><strong>Dulaglutide 0·75 mg (n=190)</strong></th>
<th scope="col" class="align-left"><strong>Insulin glargine (n=194)</strong></th>
<th scope="col" class="align-left"><strong>Dulaglutide 1·5 mg <em>vs</em> insulin glargine p value</strong></th>
<th scope="col" class="align-left"><strong>Dulaglutide 0·75 mg <em>vs</em> insulin glargine p value</strong></th>
<th scope="col" class="align-left"><strong>Overall p value</strong></th>
</tr></thead>
<tbody>
<tr class="valign-top">
<td class="align-left" colspan="2">All deaths during treatment period (52 weeks)</td>
<td class="align-left">2 (1%)</td>
<td class="align-left">7 (4%)</td>
<td class="align-left">6 (3%)</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Serious adverse events (52 weeks)</td>
<td class="align-left">38 (20%)</td>
<td class="align-left">45 (24%)</td>
<td class="align-left">52 (27%)</td>
<td class="align-left">0·113</td>
<td class="align-left">0·516</td>
<td class="align-left">0·279</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">Treatment-emergent adverse events (≥1 event; 52 weeks)</td>
<td class="align-left">172 (90%)<a name="btbl2fn1" href="#tbl2fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">168 (88%)</td>
<td class="align-left">158 (81%)</td>
<td class="align-left">0·022</td>
<td class="align-left">0·059</td>
<td class="align-left">0·039</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">Treatment-emergent adverse events (≥5% of patients; 52 weeks)</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Blood creatinine increased</td>
<td class="align-left">73 (38%)</td>
<td class="align-left">71 (37%)</td>
<td class="align-left">88 (45%)</td>
<td class="align-left">0·154</td>
<td class="align-left">0·119</td>
<td class="align-left">0·219</td>
</tr>
<tr class="valign-bottom">
<td></td>
<td class="align-left">Diarrhoea</td>
<td class="align-left">33 (17%)<a name="btbl2fn1" href="#tbl2fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">30 (16%)<a name="btbl2fn1" href="#tbl2fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">14 (7%)</td>
<td class="align-left">0·003</td>
<td class="align-left">0·011</td>
<td class="align-left">0·008</td>
</tr>
<tr class="valign-bottom">
<td></td>
<td class="align-left">Nausea</td>
<td class="align-left">38 (20%)<a name="btbl2fn2" href="#tbl2fn2" class="workspace-trigger"><sup>†</sup></a>
</td>
<td class="align-left">27 (14%)<a name="btbl2fn1" href="#tbl2fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">9 (5%)</td>
<td class="align-left">&lt;0·0001</td>
<td class="align-left">0·001</td>
<td class="align-left">&lt;0·0001</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Glomerular filtration rate decreased</td>
<td class="align-left">15 (8%)</td>
<td class="align-left">20 (11%)</td>
<td class="align-left">25 (13%)</td>
<td class="align-left">0·113</td>
<td class="align-left">0·606</td>
<td class="align-left">0·279</td>
</tr>
<tr class="valign-bottom">
<td></td>
<td class="align-left">Vomiting</td>
<td class="align-left">26 (14%)<a name="btbl2fn1" href="#tbl2fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">16 (8%)</td>
<td class="align-left">9 (5%)</td>
<td class="align-left">0·002</td>
<td class="align-left">0·108</td>
<td class="align-left">0·007</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Hypertension</td>
<td class="align-left">14 (7%)</td>
<td class="align-left">13 (7%)</td>
<td class="align-left">21 (11%)</td>
<td class="align-left">0·228</td>
<td class="align-left">0·182</td>
<td class="align-left">0·318</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Urinary tract infection</td>
<td class="align-left">14 (7%)</td>
<td class="align-left">12 (6%)</td>
<td class="align-left">21 (11%)</td>
<td class="align-left">0·228</td>
<td class="align-left">0·099</td>
<td class="align-left">0·223</td>
</tr>
<tr class="valign-bottom">
<td></td>
<td class="align-left">Upper respiratory tract infection</td>
<td class="align-left">8 (4%)<a name="btbl2fn1" href="#tbl2fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">13 (7%)</td>
<td class="align-left">19 (10%)</td>
<td class="align-left">0·032</td>
<td class="align-left">0·292</td>
<td class="align-left">0·097</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Oedema, peripheral</td>
<td class="align-left">11 (6%)</td>
<td class="align-left">12 (6%)</td>
<td class="align-left">15 (8%)</td>
<td class="align-left">0·423</td>
<td class="align-left">0·565</td>
<td class="align-left">0·709</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Influenza</td>
<td class="align-left">12 (6%)</td>
<td class="align-left">15 (8%)</td>
<td class="align-left">10 (5%)</td>
<td class="align-left">0·603</td>
<td class="align-left">0·264</td>
<td class="align-left">0·511</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Hyperkalaemia</td>
<td class="align-left">12 (6%)</td>
<td class="align-left">8 (4%)</td>
<td class="align-left">13 (7%)</td>
<td class="align-left">0·900</td>
<td class="align-left">0·287</td>
<td class="align-left">0·543</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Nasopharyngitis</td>
<td class="align-left">11 (6%)</td>
<td class="align-left">9 (5%)</td>
<td class="align-left">12 (6%)</td>
<td class="align-left">0·822</td>
<td class="align-left">0·517</td>
<td class="align-left">0·804</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Weight increased</td>
<td class="align-left">8 (4%)</td>
<td class="align-left">8 (4%)</td>
<td class="align-left">16 (8%)</td>
<td class="align-left">0·098</td>
<td class="align-left">0·084</td>
<td class="align-left">0·126</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Dizziness</td>
<td class="align-left">8 (4%)</td>
<td class="align-left">11 (6%)</td>
<td class="align-left">10 (5%)</td>
<td class="align-left">0·651</td>
<td class="align-left">0·810</td>
<td class="align-left">0·767</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Constipation</td>
<td class="align-left">12 (6%)</td>
<td class="align-left">10 (5%)</td>
<td class="align-left">6 (3%)</td>
<td class="align-left">0·128</td>
<td class="align-left">0·286</td>
<td class="align-left">0·315</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Cough</td>
<td class="align-left">7 (4%)</td>
<td class="align-left">7 (4%)</td>
<td class="align-left">14 (7%)</td>
<td class="align-left">0·105</td>
<td class="align-left">0·115</td>
<td class="align-left">0·147</td>
</tr>
<tr class="valign-bottom">
<td></td>
<td class="align-left">Hypoglycaemia</td>
<td class="align-left">3 (2%)<a name="btbl2fn1" href="#tbl2fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">9 (5%)</td>
<td class="align-left">16 (8%)</td>
<td class="align-left">0·002</td>
<td class="align-left">0·159</td>
<td class="align-left">0·010</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Adverse events of special interest (safety follow-up period)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Adjudicated kidney events</td>
<td class="align-left">79 (41%)</td>
<td class="align-left">73 (38%)</td>
<td class="align-left">91 (47%)</td>
<td class="align-left">0·254</td>
<td class="align-left">0·093</td>
<td class="align-left">0·397</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Adjudicated pancreatitis</td>
<td class="align-left">2 (1%)</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">1 (1%)</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Adjudicated death or cardiovascular event</td>
<td class="align-left">10 (5%)</td>
<td class="align-left">18 (9%)</td>
<td class="align-left">13 (7%)</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">All death</td>
<td class="align-left">3 (2%)</td>
<td class="align-left">9 (5%)</td>
<td class="align-left">6 (3%)</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Cardiovascular death</td>
<td class="align-left">2 (1%)</td>
<td class="align-left">6 (3%)</td>
<td class="align-left">4 (2%)</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Transition to end-stage renal disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="valign-bottom">
<td></td>
<td class="align-left">Transition to maintenance dialysis<a name="btbl2fn3" href="#tbl2fn3" class="workspace-trigger"><sup>‡</sup></a>
</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">2 (1%)</td>
<td class="align-left">2 (1%)</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
<td class="align-left">0·477</td>
</tr>
<tr class="valign-bottom">
<td></td>
<td class="align-left">Kidney transplantation<a name="btbl2fn4" href="#tbl2fn4" class="workspace-trigger"><sup>§</sup></a>
</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
</tr>
<tr class="valign-bottom">
<td></td>
<td class="align-left">Without reported dialysis or transplant<a name="btbl2fn5" href="#tbl2fn5" class="workspace-trigger"><sup>¶</sup></a>
</td>
<td class="align-left">8 (4%)</td>
<td class="align-left">12 (7%)</td>
<td class="align-left">14 (7%)</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
<td class="align-left">0·430</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Total</td>
<td class="align-left">8 (4%)</td>
<td class="align-left">14 (8%)</td>
<td class="align-left">16 (8%)</td>
<td class="align-left">..</td>
<td class="align-left">..</td>
<td class="align-left">0·231</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Death due to kidney diseases (confirmed by adjudication)</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">0 (0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Study treatment or study discontinuation due to death or adverse event</td>
<td class="align-left">24 (13%)</td>
<td class="align-left">19 (10%)</td>
<td class="align-left">12 (6%)</td>
<td class="align-left">0·025</td>
<td class="align-left">0·130</td>
<td class="align-left">0·082</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Study discontinuation due to death or adverse event</td>
<td class="align-left">10 (5%)</td>
<td class="align-left">9 (5%)</td>
<td class="align-left">11 (6%)</td>
<td class="align-left">0·901</td>
<td class="align-left">0·755</td>
<td class="align-left">0·947</td>
</tr>
</tbody>
</table></div>
<p class="legend"></p>
<p id="spara120">Data
 presented as n (%). The safety follow-up period included the 4 weeks 
after the treatment period. If baseline information was missing for some
 patients, the number of patients used in the denominator for percentage
 calculation was smaller than the total number of patients for the 
treatment group. Some patients did not have both baseline and at least 
one post-baseline data; therefore, the denominators can differ.</p>
<dl class="footnotes">
<dt id="tbl2fn1">*</dt>
<dd><p id="cenpara20">p&lt;0·05 versus insulin glargine.</p></dd>
<dt id="tbl2fn2">†</dt>
<dd><p id="cenpara30">p&lt;0·0001 versus insulin glargine.</p></dd>
<dt id="tbl2fn3">‡</dt>
<dd><p id="cenpara40">Patients
 with chronic dialysis reported by investigator on renal endpoint form 
or with a dialysis adverse event (searched on the Medical Dictionary for
 Regulatory Activities [MedDRA] with the preferred terms “dialysis”, 
“dialysis device insertion”, “haemodialysis”, “haemofiltration”, 
“peritoneal dialysis”, “continuous haemodiafiltration”, or “artificial 
kidney device user”).</p></dd>
<dt id="tbl2fn4">§</dt>
<dd><p id="cenpara50">Patients
 with renal transplant reported by investigator on renal endpoint form 
or with renal transplant adverse event (searched on MedDRA with the 
preferred terms “renal and liver transplant”, “renal and pancreas 
transplant”, “renal replacement therapy”, or “renal transplant”).</p></dd>
<dt id="tbl2fn5">¶</dt>
<dd><p id="cenpara60">Patients
 with end-stage renal disease without dialysis or transplant reported by
 investigator on renal endpoint form or with end-stage renal disease 
adverse event (searched on MedDRA with the preferred terms “diabetic end
 stage renal disease”, “renal failure”, or “end stage renal disease”).</p></dd>
</dl>
</div>